Remove 2003 Remove Biopharma Remove Healthcare
article thumbnail

Ten Ways to Think Differently About Small-to-Mid-Sized Pharma Launches

Eversana Intouch

Back in 2003, drugs from large pharma companies made up 36% of the late-stage R&D pipeline. These data are astonishing, given the perception that Big Pharma is the main driver of biopharma innovation. By 2018, that share had fallen by about half.

Pharma 105
article thumbnail

FINN Partners Further Expands into Asia with Addition of SPAG

PM360

SPAG, which serves global biopharma companies, health trade associations, and health provider systems, is also one of the most awarded agencies in the region having been named Global New PR Agency in 2015, Asia-Pacific Healthcare Agency of Year (2017 & 2019) at Sabre awards, and Large Agency of the Year in 2021 & 2022 by E4M (IPRCCA).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Innovations & Challenges in Brain Health

PM360

healthcare system over $800 billion annually. Collaboration across the entire ecosystem—from policymakers and regulators to healthcare providers to researchers—is critical for creating an environment where innovation can thrive. Ultimately, women’s healthcare needs are unique and demand tailored solutions.

article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

billion deal, in which Eli Lilly agreed to acquire two of POINT Biopharma Global’s late-stage radioligand therapies for oncological indications. Following his graduate studies, Dr Hoppin was an Alexander von Humboldt Fellow at the Research Center Jülich, Center for Electronics in Germany from 2003 to 2005.

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

The healthcare industry is successful in innovating new treatment paradigms ranging from small molecular to biological therapeutics to personalised medicines. The lengthy validation of defossilised organic chemicals and plastics for the healthcare sector will take several years. The path to real zero. PNAS 2022, Vol.

article thumbnail

How VMS BioMarketing Accelerated Digital Transformation with Silverline

Silver Line CRM

Through contracting with pharmaceutical and biotech companies, VMS BioMarketing provides clinical educator solutions focused on empowering healthcare providers and patients through product support, education, and training. As a leader in this market, VMS seeks constant improvement to their patient and healthcare provider experiences.

article thumbnail

How the U.S. election could impact the healthcare industries

Clarivate

Healthcare delivery has not been the hottest topic on the campaign trail this election season, despite sharp policy differences between the candidates and parties. In public speeches, she has suggested possibly expanding the program beyond Medicare, presumably to the commercial insurance market (covering 47% of all lives in the U.S.).